Author

Luis T. Campos

Observed names: L Campos, L. Campos, L. T. Campos, L.T. Campos, LUIS T. CAMPOS, Luis Campos, Luis T Campos

Observed institutions: Cleveland Clinic, Amgen (United States), University of Colorado Health, Mary Crowley Cancer Research Center, University of Chicago Medical Center, Virginia Cancer Institute, Clearview Cancer Institute, The University of Texas Health Science Center at Houston

ORCID: 0009-0006-5465-6795

Observed ORCID: 0009-0006-5465-6795

OpenAlex ID: A5002968906

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

2015 · Naiyer A Rizvi, Julien Mazières, et al. · The Lancet Oncology · 1,434

Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.

1990 · R Pazdur, J A Ajani, et al. · Journal of Clinical Oncology · 138

Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer

2011 · Johanna C. Bendell, John Nemunaitis, et al. · Journal of Clinical Oncology · 110

PDF

Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices

2007 · Vicki A. Morrison, Mitchell Wong, et al. · Journal of Managed Care Pharmacy · 109

PDF

A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma

2019 · Devalingam Mahalingam, Julio Peguero, et al. · Cancers · 98

PDF

Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens

1981 · Aman U. Buzdar, Sewa S. Legha, et al. · Cancer · 64

PDF

A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer

2017 · Lee S. Schwartzberg, Francis P. Arena, et al. · Journal of Cancer · 49

PDF

High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells

1998 · CH Weaver, T Moss, et al. · Bone Marrow Transplantation · 31

The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment

2007 · H. A. Drabkin, R. A. Figlin, et al. · Journal of Clinical Oncology · 22

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer

2014 · S.S. Ramalingam, J. Mazières, et al. · International Journal of Radiation Oncology*Biology*Physics · 19

Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer.

1997 · C H Weaver, L S Schwartzberg, et al. · PubMed · 19

Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI)

2007 · J. Stephenson, M. Schreeder, et al. · Journal of Clinical Oncology · 17

Phase I Study of Paclitaxel and Topotecan for the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

2003 · William West, Robert Birch, et al. · The Oncologist · 16

PDF

Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma

2008 · M. T. Schreeder, R. A. Figlin, et al. · Journal of Clinical Oncology · 15

A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia

2005 · G. Justice, J.F. Kessler, et al. · Annals of Oncology · 15

PDF

Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer

2015 · John Sarantopoulos, Monica M. Mita, et al. · Targeted Oncology · 13

Sequential Treatment Including High-Dose Chemotherapy With Peripheral Blood Stem Cell Support in Patients With High-Risk Stage II-III Breast Cancer

1998 · Lee S. Schwartzberg, Robert Birch, et al. · American Journal of Clinical Oncology · 11

Phase II study of single agent perifosine in patients with hepatocellular carcinoma (HCC)

2009 · L. T. Campos, J. Nemunaitis, et al. · Journal of Clinical Oncology · 10

Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer

2009 · S. Vukelja, D. Richards, et al. · Journal of Clinical Oncology · 9

Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).

2010 · D. A. Richards, J. J. Nemunaitis, et al. · Journal of Clinical Oncology · 8

Phase Ib dose-escalation trial evaluating c-MET inhibitor ARQ 197 administered in combination with gemcitabine to patients (pts) with advanced solid tumors.

2010 · L. H. Camacho, J. C. Bendell, et al. · Journal of Clinical Oncology · 7

A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer

1993 · Luis T. Campos · Cancer · 7

PDF

Clinical activity and correlative DCE-MRI imaging of G-202, a thapsigargin-based prostate-specific membrane antigen-activated prodrug, in progressive hepatocellular cancer.

2015 · Devalingam Mahalingam, Benjamin Tubb, et al. · Journal of Clinical Oncology · 6

Chemokine expression in tumor-to-tumor metastasis

2010 · JULIO S.N. PEGUERO, LUIS H. CAMACHO, et al. · Oncology Letters · 6

PDF

Longer-Term Follow-Up of a Phase 2 Study (CheckMate 063) of Nivolumab in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer

2015 · L. Horn, Naiyer A. Rizvi, et al. · Kölner Universitäts PublikationsServer (Universität zu Köln) · 5

Works count: 37

Citation count: 2,255

H-index: 15

I10-index: 18